Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

(2018) Junko Tanizaki et al.   Journal of Thoracic Oncology

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

(2017) Stefan Diem et al.   LUNG CANCER

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of responses to immune checkpoint blockade in advanced melanoma

(2017) N. Jacquelot et al.   Nature Communications

Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC).

(2017) R. Hilhorst et al.   JOURNAL OF CLINICAL ONCOLOGY

Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles.

(2017) R. Hilhorst et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results

(2016) A. Puszkiel et al.   ANNALS OF ONCOLOGY

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

(2016) Toni K. Choueiri et al.   CLINICAL CANCER RESEARCH

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

(2016) Klazien Matter-Walstra et al.   Journal of Thoracic Oncology

New and emerging targeted treatments in advanced non-small-cell lung cancer

(2016) Fred R Hirsch et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib

(2016) Gaёlle Noé et al.   Oncotarget

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

(2016) Ron Goeree et al.   JOURNAL OF MEDICAL ECONOMICS

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Persistent Antigen and Prolonged AKT–mTORC1 Activation Underlie Memory CD8 T Cell Impairment in the Absence of CD4 T Cells

(2015) Yingzhong Li et al.   JOURNAL OF IMMUNOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer

(2015) Nathan A. Pennell   SEMINARS IN ONCOLOGY

MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance

(2015) Zi-Xun Yan et al.   Biomed Research International

Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma

(2015) I Chevolet et al.   OncoImmunology

High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes

(2015) Joshua C. Anderson et al.   PLoS One

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Kinomic Profiling of Electromagnetic Navigational Bronchoscopy Specimens: A New Approach for Personalized Medicine

(2014) Joshua C. Anderson et al.   PLoS One

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

(2013) Nikolaos Patsoukis et al.   MOLECULAR AND CELLULAR BIOLOGY

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

(2013) Andliena Tahiri et al.   PLoS One

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

(2012) S. Cedrés et al.   Clinical & Translational Oncology

Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination

(2011) Marie Grøn Saelen et al.   ANGIOGENESIS

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

(2011) Eric Tartour et al.   CANCER AND METASTASIS REVIEWS

Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Multiplex Kinase Activity Profiling

(2010) Sigurd Folkvord et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Induction of Akt Activity by Chemotherapy Confers Acquired Resistance

(2009) Wei-Chien Huang et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION